Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study.

Folprecht, G; Pericay, C; Saunders, Mark P; Thomas, A; Lopez, R; Roh, J; Chistyakov, V; Höhler, T; Kim, J; Hofheinz, R; Ackland, S; Swinson, D; Kopp, M; Udovitsa, D; Hall, M; Iveson, T; Vogel, A; Zalcberg, J

Affiliation

University Cancer Center / Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany

Issue Date

2016-04-18

Metadata

Show full item record

Abstract

The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC.

Citation

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study. 2016: Ann Oncol

Journal

Annals of Oncology

URI

http://hdl.handle.net/10541/610749

DOI

10.1093/annonc/mdw176

PubMed ID

27091810

Type

Article

Language

ISSN

1569-8041

Collections

All Christie Publications